Grannus BioSciences Limited (GBL) is discovering and developing breakthrough bio-pharmaceuticals to combat inflammatory and hyperproliferative disorders. GBL’s efforts are focused on finding biologic and small molecule drugs that have the appropriate anti-inflammatory or anti-proliferative properties to regulate aberrant processes in the dermis, respiratory or gastrointestinal tract. The company has several lead clinical stage products in development. The first is a phase II small molecule pharmaceutical with application to the pre-malignant hyperproliferative condition known as Actinic Keratosis. The second is a Phase I biologic, thymosin beta 4 sulfoxide, which is a potent inhibitor of neutrophils that is formulated for dermatologic applications. Grannus has a pipeline of preclinical molecules that are also being developed for additional inflammatory applications.
Grannus seeks strategic alliances and partnerships that will support the global commercialization of its products. The Company plans to out-license rights to its product opportunities at Phase I or II to a partner in the major territories (North America, Europe, or Japan), while retaining rights in the rest of the world. Grannus also is looking to in-license additional products for development.
Last Updated: 12-12-05